ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 779

Cerebrospinal Fluid Biomarkers for Diagnosing Neuropsychiatric SLE: A Systematic Review and Meta-Analysis

Seyed-Foad Ahmadi1, Golara Zahmatkesh2, Masoud Majed3 and Sheetal Desai4, 1Department of Medicine, University of California Irvine, Orange, CA, 2Department of Psychiatry, University of New Mexico, Albuquerque, NM, 3Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, 4Medicine/Rheumatology, Unviersity of California, Irvine, Orange, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: biomarkers and neuropsychiatric disorders, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Cerebrospinal Fluid Biomarkers for Diagnosing Neuropsychiatric SLE:
A Systematic Review and Meta-analysis

 

Background/Purpose: Current guidelines recommend that in suspected neuropsychiatric SLE (NPSLE), the initial diagnostic workup should be similar to that in non-SLE patients presenting with the same manifestations. We aimed to synthesize the current best evidence regarding whether any additional cerebrospinal fluid (CSF) biomarker could be particularly beneficial in diagnosing patients with suspected NPSLE.

Methods: We completed a comprehensive search within PubMed, Embase, and CINAHL. We used a highly-sensitive search strategy comprising 67 keywords representing NPSLE and its 19 syndromes as well as CSF biomarkers. We also carried out forward and backward citation checking of the included studies and the relevant reviews using the Web of Knowledge Science Citation Index. We included the studies of the diagnostic test accuracy of any CSF biomarker for diagnosing NPSLE among patients with SLE, in which they used the ACR case definitions or other validated tools as their reference standards. Two investigators (SFA, GZ) independently replicated data extraction by using a standard form, which included an assessment of study quality as well as participant-level data to populate 2×2 contingency tables (true positives, true negatives, false positives and false negatives).

Results: We screened 2851 records and eventually included the data from 30 studies. Among the investigated 46 CSF biomarkers, only anti-NR2 and anti-neuronal antibody were shown to be highly accurate by more than one study (Figure 1). Also, anti-Smith, anti-RNP, α-klotho, fibroblast growth factor, IFN-γ, and interleukins 2, 5, 15, and 17 were each suggested to be highly accurate by a single study. The other CSF biomarkers were shown to be inaccurate by one study or more (Figure 2).

Conclusion: The CSF anti-NR2 and anti-neuronal antibody may be valuable additions to the routine initial workup done for suspected neuropsychiatric SLE. As these studies are both sensitive and specific, they can effectively change the post-test probability of NPSLE over a wide range or pre-test probabilities. Other biomarkers such as anti-Smith may have substantial diagnostic accuracy as well. However, their routine use requires more support by strong evidence.


Disclosure: S. F. Ahmadi, None; G. Zahmatkesh, None; M. Majed, None; S. Desai, None.

To cite this abstract in AMA style:

Ahmadi SF, Zahmatkesh G, Majed M, Desai S. Cerebrospinal Fluid Biomarkers for Diagnosing Neuropsychiatric SLE: A Systematic Review and Meta-Analysis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/cerebrospinal-fluid-biomarkers-for-diagnosing-neuropsychiatric-sle-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cerebrospinal-fluid-biomarkers-for-diagnosing-neuropsychiatric-sle-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology